Selective use of vandetanib in the treatment of thyroid cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Selective use of vandetanib in the treatment of thyroid cancer

Published:2015-07 Issue: Volume: Page:3459
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Antonelli Alessandro,Fallahi Poupak,Di Bari Flavia,Ferrari Silvia Martina,Spisni Roberto,Materazzi Gabriele,Miccoli Paolo,Benvenga Salvatore

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure and activity relationship analysis of xanthones from mangosteen: Identifying garcinone E as a potent dual EGFR and VEGFR2 inhibitor;Phytomedicine;2024-01

2. Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches;Life Sciences;2023-11

3. Discovery of highly potent and selective VEGFR2 kinase inhibitors for the treatment of rheumatoid arthritis;European Journal of Medicinal Chemistry;2023-09

4. Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes;Cancer Management and Research;2023-04

5. Future treatment of Diabetes – Tyrosine Kinase inhibitors;Journal of Diabetes & Metabolic Disorders;2022-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP